Skip to main content
Displaying 1 - 12 of 14
Display:
12
24
48
Immune-Mediated and Cholestatic Diseases
5
GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
5
GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
5
GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
5
GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
5
GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy